Nevertheless, several studies have explored the use of peripheral blood (PB) as an input for the detection of residual disease, and the MRD obtained from the PB is already being incorporated into AML protocols for clinical decision making (e.g., CBF and NPM1 AML Pethema protocols with the MRD by RT-qPCR for follow-up RUNX1-RUNX1T1, CBFb-MYH11, and NPM1 mutations) [51,52,53]. This evidence concerns the gene CBFB and acute myeloid leukemia.